Consolidated Statements of Cash Flows (USD $) In Thousands	12 Months Ended
	Apr. 02, 2011		Apr. 03, 2010		Mar. 28, 2009
Cash Flows from Operating Activities:
Net income	$ 79,980		$ 58,370		$ 59,304
Non cash items:
Depreciation and amortization	48,145		43,236		36,462
Stock compensation expense	10,810		10,267		10,181
Deferred tax expense	5,782		2,592		1,645
Loss/(gain) on sales of property, plant and equipment	674		(435)		(124)
Unrealized gain from hedging activities	(614)		(1,368)		3,812
Contingent consideration income	(1,894)		(2,345)
(Reversal)/accretion of interest expense on contingent consideration	(416)		588
Asset impairment			15,686
Change in operating assets and liabilities:
(Increase)/decrease in accounts receivable, net	(3,920)		4,364		2
(Increase)/decrease in inventories	(2,560)		(1,665)		(11,236)
Decrease in prepaid income taxes	1,680		7,254		(2,913)
Decrease in other assets and other long-term liabilities	(470)		(13,809)		(4,241)
Tax benefit of exercise of stock options	4,941		2,670		3,368
(Decrease)/increase in accounts payable and accrued expenses	(18,683)		5,263		20,104
Net cash provided by operating activities	123,455		130,668		116,364
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(46,669)		(56,304)		(56,379)
Proceeds from sale of property, plant and equipment	1,468		1,785		2,383
Acquisition of ACCS	(6,229)
Acquisition of Global Med Technologies	(128)		(58,052)
Acquisition of SEBRA			(12,845)
Acquisition of Neoteric			(6,613)
Acquisition of Altivation					(3,545)
Acquisition of Medicell			(306)		(2,459)
Net cash used in investing activities	(51,558)		(132,335)		(60,000)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(632)		(754)		(694)
Net (decrease)/increase in short-term loans	(15,153)		6,184		(5,580)
Employee stock purchase plan	3,681		2,909		2,659
Exercise of stock options	40,896		17,270		25,406
Excess tax benefit on exercise of stock options	3,124		421		7,470
Share repurchase	(50,000)		(40,000)		(59,998)
Net cash used in financing activities	(18,084)		(13,970)		(30,737)
Effect of exchange rates on cash and cash equivalents	1,332		478		(2,459)
Net Increase in Cash and Cash Equivalents	55,145		(15,159)		23,168
Cash and Cash Equivalents at Beginning of Year	141,562	[1]	156,721		133,553
Cash and Cash Equivalents at End of Period	196,707		141,562	[1]	156,721
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	5,069		7,833		6,818
Debt assumed from acquisition			5,132
Supplemental Disclosures of Cash Flow Information:
Interest paid	487		563		545
Income taxes paid	$ 16,669		$ 21,519		$ 19,391

[1] Certain balances were revised to reflect updates to our purchase price allocation of our Global Med acquisition - See Note 3, Acquisitions.